Sana Biotechnology (SANA) stock soared after Phase 1 data for its cell therapy which, according to Morgan Stanley, has ...

Sana Biotechnology has shared early data for its investigational allogeneic cell therapy being studied in one patient with ...

Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...

Sana Biotechnology Inc.'s stock soared over 200% on Wednesday, on track to mark its best day on record, amid trading volumes ...

Sana Biotechnology's first-in-human study shows UP421 pancreatic islet cells surviving and functioning in type 1 diabetes ...

Sana stock soars on diabetes therapy data, UniQure's offering, BioInvent's lymphoma success, Alpha's Zunveyl deal, Neumirna funding, and Cassava's layoffs.

Positive results from clinical trials often give biotechnology companies a boost, but this one was big. Shares of Sana Biotechnology —a firm with a market capitalization of less than $400 million as ...

The stock could soar even higher. Before the results were announced, the average target price among three analysts surveyed ...

Sana Biotechnology reported no revenues for the third quarter of 2024, which was in line with expectations for a clinical-stage biotech company. The company's research and development (R&D ...

Sana Biotechnology reported no revenues for the third quarter of 2024, which was in line with expectations for a clinical-stage biotech company. The company's research and development (R&D) expenses ...

Shares of Sana Biotechnology Inc. (NASDAQ: SANA) were trading at $4.97, up $3.32, or 201%, on first results from an investigator-sponsored, first-in-human study transplanting UP-421, an allogeneic ...

Nevin Al Sukari - Sana'a - Eugene Spector, a US citizen jailed for a total of 15 years this week after a Moscow court ...